Bellevue Group AG Buys 82,548 Shares of Silk Road Medical, Inc (NASDAQ:SILK)

Bellevue Group AG increased its holdings in Silk Road Medical, Inc (NASDAQ:SILK) by 5.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,518,230 shares of the company’s stock after acquiring an additional 82,548 shares during the quarter. Bellevue Group AG owned about 3.85% of Silk Road Medical worth $27,814,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. CWM LLC boosted its position in Silk Road Medical by 151.5% in the fourth quarter. CWM LLC now owns 2,563 shares of the company’s stock worth $31,000 after purchasing an additional 1,544 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Silk Road Medical by 1,293.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,523 shares of the company’s stock worth $31,000 after purchasing an additional 2,342 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Silk Road Medical by 879.1% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,210 shares of the company’s stock valued at $52,000 after acquiring an additional 3,780 shares during the last quarter. Quest Partners LLC purchased a new position in shares of Silk Road Medical in the fourth quarter valued at $62,000. Finally, Tower Research Capital LLC TRC raised its stake in Silk Road Medical by 369.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,834 shares of the company’s stock valued at $96,000 after purchasing an additional 6,165 shares in the last quarter.

Silk Road Medical Trading Up 0.0 %

Silk Road Medical stock traded up $0.01 during trading on Friday, hitting $27.02. The company had a trading volume of 1,077,613 shares, compared to its average volume of 1,237,167. The company has a current ratio of 11.05, a quick ratio of 9.62 and a debt-to-equity ratio of 0.52. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -19.72 and a beta of 1.52. Silk Road Medical, Inc has a 1-year low of $6.08 and a 1-year high of $27.19. The company’s 50 day simple moving average is $24.75 and its 200-day simple moving average is $19.94.

Silk Road Medical (NASDAQ:SILK) last issued its quarterly earnings results on Tuesday, April 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.04. Silk Road Medical had a negative net margin of 29.02% and a negative return on equity of 35.47%. The company had revenue of $48.50 million during the quarter, compared to the consensus estimate of $44.67 million. During the same quarter in the previous year, the firm earned ($0.43) earnings per share. The firm’s quarterly revenue was up 20.9% on a year-over-year basis. As a group, analysts expect that Silk Road Medical, Inc will post -1.43 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Stifel Nicolaus restated a “hold” rating and issued a $27.50 target price (up from $23.00) on shares of Silk Road Medical in a report on Wednesday, July 17th. Argus lowered shares of Silk Road Medical from a “buy” rating to a “sell” rating in a research report on Thursday, July 11th. Piper Sandler upped their price target on shares of Silk Road Medical from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, May 1st. JPMorgan Chase & Co. lifted their target price on Silk Road Medical from $19.00 to $21.00 and gave the company a “neutral” rating in a research report on Wednesday, May 1st. Finally, Lake Street Capital reissued a “hold” rating and set a $27.50 price objective (down from $28.00) on shares of Silk Road Medical in a report on Tuesday, June 18th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $21.50.

About Silk Road Medical

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure.